Thanks. The BP report is very encouraging and you've quoted the essentials, to which I would add:-
"The efficacy data is a slam dunk in our view, and we believe payers will be compelled to reimburse"
BP allows that they expect the realised price to be at a discount to the list price, but they also note that the price is twice their previous estimate
"This indicative pricing is 2x our previous estimate"
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.57 |
Change
-0.075(4.57%) |
Mkt cap ! $1.999B | |||
| Open | High | Low | Value | Volume |
| $1.62 | $1.63 | $1.56 | $7.148M | 4.531M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 10000 | $1.57 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.57 | 76923 | 1 |
View Market Depth
| Last trade - 16.10pm 23/06/2025 (20 minute delay) ? |
| MSB (ASX) Chart |